Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality

BACKGROUND: Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II, remissio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Dong-Jing, Zhang, Qiaoyi, Shi, Ling, Borentain, Stephane, Guo, Shien, Mathews, Maju, Anjo, Joana, Nash, Abigail I., O’Hara, Marguerite, Canuso, Carla M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416356/
https://www.ncbi.nlm.nih.gov/pubmed/37568081
http://dx.doi.org/10.1186/s12888-023-05017-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416356/
https://www.ncbi.nlm.nih.gov/pubmed/37568081
http://dx.doi.org/10.1186/s12888-023-05017-y

Ejemplares similares